Biomedical nanomaterials

Content: Cover
 Title Page
 Copyright
 Contents
 List of Contributors
 Chapter 1 Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials
 1.1 Introduction
 1.2 Commonly Utilized NMs in Pharmaceutical Research
 1.2.1 Natural NMs
 1.2.1.1 Lipid-Based NMs
 1.2.1.2 Protein-Based NMs
 1.2.1.3 Polysaccharide-Based NMs
 1.2.2 Synthetic NMs
 1.2.2.1 Diversity of Synthetic NMs in Forms
 1.2.2.2 Drug Release Behaviors
 1.2.3 Inorganic NMs
 1.2.4 Other NMs
 1.3 In vivo Biodistribution and the Evolving Targeting Principles for NMs
 1.3.1 Organ Distribution versus Cell-Specific Targeting 1.3.2 Targeting Delivery Strategies1.4 Processing NMs by the Biological Systems
 1.4.1 Anatomic Basis of NMs' in vivo Biodistribution Behavior
 1.4.2 Factors Affecting in vivo Biodistribution of NMs
 1.4.2.1 Size
 1.4.2.2 Zeta Potential
 1.4.2.3 Shape and Deformability
 1.4.2.4 Hydrophilicity and Hydrophobicity
 1.4.3 Metabolism and Elimination of NMs
 1.4.3.1 Common Metabolism
 1.4.3.2 Degradable versus Nondegradable NMs
 1.4.3.3 Free Drug versus Drug Encapsulated by NMs
 1.5 Rational Design of Long-Circulating NMs
 1.5.1 NMs with Optimal Physicochemical Characters 1.5.2 Surface Modification to Improve the Intrinsic Features of NMs1.6 Mathematic Simulation of NM-Mediated Cancer Drug Delivery
 1.6.1 Progress: From Experiment to Simulation
 1.6.2 Compartment Models for PK Assessment of NMs
 1.6.3 Physiologically Based Compartment Models
 1.6.3.1 Protocols of Building a PBPK Model for NMs
 1.6.3.2 Examples
 1.6.4 Brief Summary
 1.7 Experimental PK Data of the Applied NMs
 1.7.1 PK Data of NMs Without Drugs
 1.7.2 PK Differences Between Drugs Encapsulated by Different NMs
 1.7.3 Reciprocal Blood and Tissue PK 1.7.4 PK Differences Between Different Components of the Drug-NM System1.7.5 PK Variations Among Different Routes of Administration
 1.8 Perspectives
 1.8.1 Development of NMs
 1.8.2 Pharmacokinetic Study and Model Development
 References
 Chapter 2 Targeted Dendrimers for Cancer Diagnosis and Therapy
 2.1 Introduction
 2.2 Targeted Dendrimers for Cancer Therapy
 2.2.1 Low Molecular Weight Ligand-Modified Dendrimers
 2.2.1.1 Folic Acid-Modified Dendrimers
 2.2.1.2 Carbohydrate-Modified Dendrimers
 2.2.1.3 Biotin-Modified Dendrimers
 2.2.1.4 Riboflavin-Modified Dendrimers 2.2.1.5 Estrogen-Modified Dendrimers2.2.2 Macromolecular Ligand-Modified Dendrimers
 2.2.2.1 Antibody-Modified Dendrimers
 2.2.2.2 Transferrin (Tf)- and Lactoferrin (Lf)-Modified Dendrimers
 2.2.2.3 EGF- and Fibroblast Growth Factor (FGF)-Modified Dendrimers
 2.2.2.4 Peptide-Modified Dendrimers
 2.2.2.5 Aptamer-Modified Dendrimers
 2.2.2.6 Hyaluronic Acid (HA)-Modified Dendrimers
 2.2.3 Dual-Targeting Ligand-Modified Dendrimers
 2.3 Targeted Dendrimers for Cancer Diagnosis
 2.3.1 Targeted Dendrimers in CT
 2.3.2 Targeted Dendrimers in SPECT
 2.3.3 Targeted Dendrimers in MRI